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Abstract
Background
Fetal exposure to maternal diabetes increases the risk of type 2 diabetes (T2DM), possibly
mediated by epigenetic mechanisms. Low blood TXNIP DNA methylation has been associ-
ated with elevated glucose levels and risk of T2DM, and increased skeletal muscle TXNIP
gene expression was reported in subjects with impaired glucose metabolism or T2DM. Sub-
cutaneous adipose tissue (SAT) and skeletal muscle play a key role in the control of whole
body glucose metabolism and insulin action. The extent to which TXNIP DNA methylation
levels are decreased and/or gene expression levels increased in SAT or skeletal muscle of
a developmentally programmed at-risk population is unknown.
Objective and methods
The objective of this study was to investigate TXNIP DNA methylation and gene expression
in SAT and skeletal muscle, and DNA methylation in blood, from adult offspring of women
with gestational diabetes (O-GDM, n = 82) or type 1 diabetes (O-T1DM, n = 67) in preg-
nancy compared with offspring of women from the background population (O-BP, n = 57).
Results
SAT TXNIP DNA methylation was increased (p = 0.032) and gene expression decreased (p
= 0.001) in O-GDM, but these differences were attenuated after adjustment for confounders.
Neither blood/muscle TXNIP DNA methylation nor muscle gene expression differed
between groups.
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Conclusion
We found no evidence of decreased TXNIP DNA methylation or increased gene expression
in metabolic target tissues of offspring exposed to maternal diabetes. Further studies are
needed to confirm and understand the paradoxical SAT TXNIP DNA methylation and gene
expression changes in O-GDM subjects.
Introduction
Fetal exposure to maternal diabetes is associated with increased risk of metabolic disease in off-
spring, and this association is greater than the expected genetic risk associated with a family
history of diabetes [1–5]. Increasing evidence indicates that epigenetic mechanisms play a role
in mediating this increased risk of metabolic disease associated with fetal exposure to diabetes
in pregnancy [6–10].
Addition of methyl groups at cytosine-guanine dinucleotides (CpGs) in regulatory/pro-
moter regions in DNA, known as DNA methylation, typically leads to transcriptional repres-
sion and decreased expression of the gene in question [11]. Thioredoxin-interacting protein
(TXNIP) is a ubiquitously expressed protein that inhibits the key cellular antioxidant protein
thioredoxin, and thus regulates the cellular redox state, promoting oxidative stress and apopto-
sis [12, 13]. A high TXNIPDNA methylation percentage at CpG site cg19693031 in blood has
consistently been associated with lower fasting blood glucose, HbA1c and/or HOMA-IR levels,
as well as a lower prevalence and a decreased risk of type 2 diabetes (T2DM) in different stud-
ies [14–19].
TXNIP gene expression is stimulated by glucose and suppressed by insulin in a variety of
cells and tissues, including skeletal muscle and adipose tissue and cells [20–22], and TXNIP
gene expression is upregulated in skeletal muscle samples from subjects with diabetes and pre-
diabetes [22]. Increased TXNIP expression inhibits insulin-mediated glucose uptake in skeletal
muscle and adipocytes, while TXNIP inhibition increases glucose uptake [22, 23]. Thus,
TXNIP is a glucose and insulin-sensitive switch regulating glucose metabolism by controlling
glucose uptake in the periphery.
Altogether, the abovementioned results implicate altered TXNIPDNA methylation and/or
expression as a potential pathogenic mechanism in the development of T2DM. However,
almost all studies of TXNIPDNA methylation are performed on circulating blood cells [14, 16,
18, 19], and information on methylation in other metabolically relevant tissues such as fat and
skeletal muscle is lacking. Moreover, direct evidence of epigenetic changes caused by fetal pro-
gramming of diabetes is scarce, with only a few target genes identified in metabolically active
tissues. We have access to metabolically active tissues in a unique cohort of subjects exposed to
maternal diabetes in pregnancy, and with a known predisposition to T2DM.
The aim of our study was to investigate whether exposure to intrauterine hyperglycemia
may be associated with changes in TXNIPDNA methylation in subcutaneous adipose tissue
(SAT), skeletal muscle and blood as well as TXNIP gene expression levels in SAT and skeletal
muscle. Based on previous studies showing an increased risk of T2DM in offspring exposed to
intrauterine hyperglycemia, we expected decreased TXNIPDNA methylation in SAT, skeletal
muscle and blood, and conversely increased TXNIP gene expression levels in SAT and skeletal
muscle in offspring exposed to maternal diabetes compared to controls.
Epigenetic changes in TXNIP with fetal exposure to maternal diabetes in pregnancy
PLOS ONE | https://doi.org/10.1371/journal.pone.0187038 October 27, 2017 2 / 18
data requests may be sent: Danish Data Protection
Agency Borgergade 28, 5. 1300 Copenhagen
Denmark.
Funding: This work was supported by the Danish
Council for Strategic Research, the Novo Nordisk
Foundation, Danish Diabetes Academy, Augustinus
Foundation, Danish Diabetes Association, The A.P.
Møller Foundation for the Advancement of Medical
Science, European Foundation for the Study of
Diabetes (EFSD), and The Research Fund of
Rigshospitalet. ERM has received honorarium from
Novo Nordisk A/S for talks. The funders had no
role in study design, data collection and analysis,
decision to publish or preparation of the
manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: AV is currently
employed by AstraZeneca, Mo¨lndal, Sweden and
AHO is currently employed by Novo Nordisk A/S.
ERM and PD are participating in a multinational
study in collaboration with Novo Nordisk A/S and
ERM has received honorarium from Novo Nordisk
A/S for talks. LH, LK, NSH, CB, LG, and TDC have
declared that no competing interests exist. There
are no patents, products in development or
marketed products to declare. This does not alter
our adherence to all the PLOS ONE policies on
sharing data and materials.
Methods
Study design and setting
The current study is the second follow-up in an observational study of a birth cohort exposed
to diabetes in pregnancy. Material from the same cohort has been used previously, and study
design, inclusion criteria and baseline data have been described in detail elsewhere [1, 2, 24,
25]. The participants were adult offspring of women with either gestational diabetes (O-GDM,
N = 82) or type 1 diabetes (O-T1DM, N = 67) in pregnancy, and a randomly selected control
group consisting of offspring of women from the background population (O-BP, N = 57). Par-
ticipants were born in the period between 1978–1985 at Rigshospitalet, in Copenhagen, Den-
mark, and were between 26–35 years of age at the time of examination. The original cohort
consisted of 1066 offspring. Of these 254 belonged to a group that was not re-invited for the
second follow-up, leaving a total of 812 potentially eligible offspring in the original cohort, 597
of whom participated in the first cross-sectional follow-up study in 2003–2005 [1, 2, 24]. Of
these, 456 participants were eligible for participation in the second follow-up, and 250 were
lost or excluded for various reasons, resulting in a total of 206 participants (25% of the original
cohort or 45% from the first follow-up in the current study as previously described [24, 25]
(Fig 1).
Diabetes in pregnancy in Denmark during the period of 1978–1985:
Maternal selection criteria
In the abovementioned period in Denmark, screening for gestational diabetes in pregnancy
was based on the presence of one or more risk factors and two consecutive fasting blood glu-
cose values 4.1 mmol/l. The definitive GDM diagnosis was then confirmed by a 3-hour 50-g
oral glucose tolerance test (OGTT), which was defined as abnormal if two or more blood glu-
cose values exceeded the mean +3 SD of a standard reference curve for a group of healthy, nor-
mal-weight, non-pregnant women without a family history of diabetes [26]. The mean + 3SD
for venous plasma glucose values were 6.4 mmol/l at t = 0, 10.1 mmol/l at t = 30 min, 7.6
mmol/l at both t = 120 and 150 min, and 6.6 mmol/l at t = 180 min [27]. Only women with
diet-treated GDM were included, in order to minimize potential risk of misclassification from
other types of diabetes (e.g. early stage T1DM, undiagnosed T2DM and MODY).
Mothers with type 1 diabetes fulfilled the following criteria: onset of diabetes at age 40 or
younger, classical history of hyperglycemia symptoms before diagnosis, and insulin treatment
started 6 months or less after diagnosis.
Mothers from the background population were unselected women routinely referred to
Rigshospitalet for antenatal care and delivery in the same period (1978–1985) [2]. They were
identified from maternal medical records of all deliveries in the study period and sampled con-
secutively according to maternal day of birth
Outcome variables
Outcomes of interest were TXNIPDNA methylation in SAT, skeletal muscle and blood, and
gene expression in SAT and skeletal muscle in offspring exposed to maternal diabetes com-
pared to unexposed offspring. Furthermore, we studied associations between maternal blood
glucose levels on one hand, and offspring TXNIPDNA methylation or gene expression on the
other hand, as well as correlations between offspring TXNIPDNA methylation and gene
expression levels and markers of offspring glucose and insulin sensitivity.
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Fig 1. Study design- subjects participating and lost to follow-up. O-BP: offspring of women from the
background population; O-GDM: offspring of women with gestational diabetes; O-NoGDM: offspring of
women with risk factors for gestational diabetes but normal glucose tolerance in pregnancy (not invited to
participate in second round of follow-up); O-T1DM: offspring of women with type 1 diabetes in pregnancy.
*O-NoGDM (n = 254) were not invited to participate in the second round of follow-up, leaving 812 eligible
offspring from the original cohort (1066–254 = 812) divided into the three groups O-GDM, O-T1DM and O-BP.
https://doi.org/10.1371/journal.pone.0187038.g001
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Exposure variables
Exposure to maternal diet-treated GDM or T1DM, as determined by offspring group, was the pri-
mary exposure variable. GDM mothers underwent OGTT’s during pregnancy and information
regarding fasting and 2-hour blood glucose levels was available for these women. The procedure
for T1DM pregnancies in the baseline period involved hospitalization in the 1st and 3rd trimes-
ter with measurement of blood glucose 7 times a day for 3 days, and mean glucose values were
calculated from these 3-day profiles in the 1st and 3rd pregnancy trimester. Maternal pregnancy
blood glucose values for GDM and T1DM mothers were thus also used as exposure variables.
Confounders
Multivariate regression analyses were performed to strengthen the hypothesis that observed
differences in TXNIPDNA methylation and gene expression between the exposure and con-
trol groups were due to exposure to maternal diabetes. Maternal pre-pregnancy BMI, age at
delivery, smoking status, family history of diabetes, as well as offspring gender and age at fol-
low-up were used as potential confounders in regression analyses.
Examination of participants at follow-up
The participants were recruited and examined in the period between May 2012 and September
2013. After an overnight fast, they underwent SAT biopsies from the abdomen and skeletal
muscle biopsies from the vastus lateralis muscle of the thigh using a Bergstrom needle. A total
of 70–300 mg adipose tissue and 50–200 mg skeletal muscle was obtained, and the tissue was
immediately frozen in liquid nitrogen and stored at -80˚C until analysis.
The biopsies were followed by a 2-hour, 75-g oral OGTT, and clinical examination with
measurements of height, weight, waist and hip circumference, blood pressure, and a dual x-ray
absorptiometry (DEXA) whole-body scanning (GE Medical Systems Lunar Prodigy Advance,
Fairfield, Connecticut, USA) to determine body composition. Body fat percent (BF%) was
defined as total fat mass divided by total body mass. Insulin resistance was calculated using
homeostatic model assessment (HOMA-IR) [28] and glucose tolerance was assessed according
to WHO criteria of 2006 [29].
The study was in accordance with the Declaration of Helsinki and approved by the Danish
National Committee on Health Research Ethics. All subjects received written and oral infor-
mation and provided written consent before participation.
DNA methylation
We extracted genomic DNA from the skeletal muscle biopsies using the DNeasy blood and tis-
sue Kit, from the SAT biopsies using the QIAamp DNA Mini Kit, and from blood (buffy
coats) using the QIAamp 96 DNA blood kit (all Qiagen). A total of 10–40 mg SAT and skeletal
muscle tissue was used to extract 500 ng (skeletal muscle and blood) and 400 ng (SAT) DNA,
respectively, which was then bisulfite converted using the EpiTect Bisulfite Kit (Qiagen). DNA
methylation was then measured at CpG site cg19693031, located in the 3’UTR region approxi-
mately 3000 base pairs downstream from the TXNIP transcription start site, using bisulfite pyr-
osequencing. Methylation differences at this CpG site may alter the binding affinity of
methylation-sensitive transcription regulators [16]. PyroMark Assay Design 2.0 software was
used to design primers, and pyrosequencing of the PCR products was performed with the Pyr-
oMarkQ96 instrument (Qiagen). Primer sequences were as follows: forward primer, 5´-TGT
TTGTTGGATGGGTTTAAAAATAATT-3´, reverse primer (biotinylated), 5´-AAACCTCCA
AAAAACCTTAAAAAACTT-3´, sequencing primer, 5´GGGTTAGGTAAAAATGG-3´.
Epigenetic changes in TXNIP with fetal exposure to maternal diabetes in pregnancy
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Gene expression
20–90 mg SAT and skeletal muscle tissue was used to extract 400 ng RNA using the miRNEasy
Mini Kit (Qiagen) for SAT and the Trizol method for skeletal muscle. RNA concentrations
were measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific). RNA was
synthesized to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) using random
primers. Target-specific TXNIP gene primers were then used to amplify the TXNIP gene from
our cDNA. These were designed using human specific databases (Ensembl Genome Browser)
and Universal Probe Library (Roche Applied Science). The primer sequences were: forward
primer, 5´-GGCTAAAGTGCTTTGGATGC-3´, and reverse primer: 5´-AGGTCTCATGAT
CACCATCTCA-3´. Primers were synthesized by DNA Technology and optimization was per-
formed before use to determine primer working concentrations. TXNIPmRNA expression
levels were evaluated in duplicates using SYBR Green mastermix by reverse transcription
quantitative PCR (RT qPCR) using the ABI PRISM 7900 ViiA7 Real-Time PCR System
(Applied Biosystems), where the PCR products are measured as they accumulate in “real-
time”. Real-time qPCR is a highly sensitive and specific technique, and is considered to be the
gold standard by which a very low number of RNA molecules can be detected. SYBR Green
dye has the potential to generate false positive signals as it can bind to any double-stranded
DNA in the sample (for example primer-dimers), and to overcome this problem we included
non-reverse transcriptase controls to test for the presence of contaminating DNA, and we
tested for the presence of primer-dimers by melting-curve analysis where we accepted primers
with only one top. We measured mRNA expression in duplicates to take technical variation
into account, and a variation of up to 5% was accepted between the two values, as per standard
recommendation and protocol [30]. The variation was below 1% for all mRNA samples in this
study. Fold changes in mRNA expression levels were calculated after normalization to the
hypoxanthine phosphoribosyl transferase 1 (HPRT1) reference gene (forward primer: 5´-TG
ACCTTGATTTATTTTGCATACC-3´, reverse primer: 5´-CGAGCAAGACGTTCAGTCCT-3´).
Statistics
All statistical analyses were performed using IBM SPSS statistics version 22. All comparisons
were to the O-BP control group, performed using independent samples Student’s t-test for
comparison of means between continuous variables or chi-squared test for comparison of pro-
portions for categorical variables. Nonparametric data was log-transformed prior to entering
statistical analysis. Forced-entry multivariate linear regression analysis was used to examine
the impact of maternal metabolic disease on offspring DNA methylation and gene expression.
We used two models—in model 1 we corrected for maternal pre-pregnancy BMI, age at deliv-
ery, smoking status, family history of diabetes, as well as offspring gender and age. Model 2
was a post-hoc analysis in which we added offspring HOMA-IR, HbA1c and total body fat %
as potential mediators, as these have been shown to be associated with TXNIPDNA methyla-
tion and gene expression. Missing values were excluded listwise (complete case analyses) in
regression analyses. TXNIP expression levels were log transformed prior to linear regression
analysis to meet assumptions of homoscedasticity. A two-sided p-value<0.05 was considered
statistically significant for all analyses
Results
Baseline clinical data
Characteristics of the study population and maternal data have been previously published [24]
and are shown in Table 1. Offspring exposed to maternal diabetes had significantly higher
Epigenetic changes in TXNIP with fetal exposure to maternal diabetes in pregnancy
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Table 1. Baseline clinical characteristics in adult offspring of women with gestational diabetes (O-GDM) or type 1 diabetes (O-T1DM) compared to
offspring of women from the background population (O-BP).
O-GDM O-T1DM O-BP O-GDM vs. O-BP p-
value
O-T1DM vs. O-BP p-
value
N (Total = 206) 82 67 57
Maternal data (1978–85)
Age at delivery (years) 30.4(5.2) 26.4 (4.7) 26.8 (4.6) <0.001 0.645
Pregestational BMI (kg/m2) 24.3 (5.6) 21.7 (1.9) 21.2 (3.5) <0.001 0.301
Pregestational overweight (BMI 25 kg/m2) 34% (28/82) 8% (5/64) 12% (7/57) 0.003 0.412
Family history of diabetes (yes vs. no) 26% (21/82) 25% (17/67) 16% (9/57) 0.166 0.191
Smoking status (yes vs. no)* 32% (22/69) 63% (37/59) 58% (26/45) 0.006 0.610
Fasting blood glucose before OGTT (mmol/
l)
5.2 (0.6) NA NA NA NA
120 min blood glucose during OGTT (mmol/
l)
7.9 (1.8) NA NA NA NA
Mean blood glucose in first trimester NA 9.0 (3.0) NA NA NA
Mean blood glucose in third trimester NA 6.7 (1.6) NA NA NA
Offspring anthropometric data
Age (year) 30.2 (2.1) 30.8 (2.4) 30.8 (2.4) 0.183 0.879
Gender (male) 52% (43/82) 46% (31/67) 46% (26/57) 0.429 0.942
Weight (kg) 77.8 (17.4) 78.3 (17.9) 75.3 (16.5) 0.398 0.331
Height (meter) 1.76 (0.10) 1.74 (0.10) 1.74 (0.10) 0.481 0.676
Total body fat (%) 29.8% (0.1) 31.4% (0.1) 28.7% (0.1) 0.428 0.093
BMI (kg/m2) 25.2 (5.1) 26.0 (5.9) 24.6 (3.9) 0.493 0.113
Obese (BMI 30 kg/m2) 15% (12/82) 16% (11/67) 7% (4/57) 0.166 0.110
Results of OGTTa
Fasting plasma glucose (mmol/l) "door
step"
5.0 (0.7) 4.9 (0.4) 4.9 (0.3) 0.245 0.381
30 min. plasma glucose (mmol/l) 8.2 (1.7) 7.8 (1.7) 7.3 (1.6) 0.006 0.125
120-min plasma glucose (mmol/l) 6.0 (1.8) 6.3 (1.7) 5.3 (1.2) 0.016 0.001
HbA1C_IFCC (mmol/mol) 35.1 (3.6) 34.5 (3.3) 34.0 (2.8) 0.076 0.415
HbA1C_DCCT (%) 5.4 (0.3) 5.3 (0.3) 5.3 (0.3) 0.079 0.569
Abnormal glucose tolerance (IFG, IGT or
T2DM)
13% (11/82) 13% (9/67) 5% (3/57) 0.116 0.125
IFG 1% (1/82) 0% (0/67) 0% (0/57) 0.403 NA
IGT 7% (6/82) 10% (7/67) 5% (3/57) 0.628 0.291
Both IFG and IGT 1% (1/82) 0%(0/67) 0% (0/57) 0.403 NA
Pre-diabetes (IFG and/or IGT) 10% (8/82) 10% (7/67) 5% (3/57) 0.334 0.291
T2DM (diagnosed at follow-up) 2% (2/82) 1.5% (1/67) 0% (0/57) 0.235 0.354
T2DM (previously known) 1% (1/82) 1.5%(1/67) 0% (0/57) 0.403 0.354
HOMA-IRb 1.77 (1.56–
2.02)
1.95 (1.71–
2.22)
1.72 (1.47–
2.02)
0.784 0.222
Plasma samplesb
Fasting insulin (pmol/l) 49 (43–55) 54 (48–61) 49 (42–56) 0.953 0.255
120 min. insulin (pmol/l) 252 (210–304) 281 (240–329) 223 (185–268) 0.350 0.056
Triglycerides (mmol/l) 0.89 (0.81–
0.98)
0.84 (0.76–
0.93)
1.00 (0.76–
1.31)
0.391 0.233
LDL-cholesterol (mmol/l) 2.72 (2.57–
2.87)
2.64 (2.48–
2.81)
2.79 (2.60–
3.00)
0.540 0.233
HDL-cholesterol (mmol/l) 1.33 (1.26–
1.41)
1.44 (1.37–
1.52)
1.36 (1.26–
1.48)
0.605 0.241
(Continued )
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2-hour OGTT glucose values, and for O-GDM, higher 30-minute glucose and HbA1c values.
There were no other differences in the majority of baseline and anthropometric data between
the two exposure groups and the control group. The GDM women had a significantly higher
age at delivery, higher pregestational BMI, and a higher proportion of these women were
smokers and had pregestational overweight compared to the women from the background
population, as previously described [24]
TXNIP DNA methylation and gene expression in subcutaneous adipose
tissue
In univariate analyses, TXNIPDNA methylation in SAT was increased in O-GDM compared
to O-BP (p = 0.032) (Fig 2A). This difference was attenuated after adjustment for confounders
in model 1 (p = 0.063) and additional adjustment for mediators in model 2 (p = 0.166). There
was no difference in DNA methylation levels between O-T1DM and O-BP (Table 2).
TXNIP expression was decreased in SAT from O-GDM (p = 0.001) and near-significantly
decreased in O-T1DM (p = 0.058) compared to O-BP (Fig 3A). Adjusting for confounders
(model 1), maternal GDM remained negatively associated with SAT TXNIP expression
(p = 0.024), while this association was attenuated when further adjusted for mediators in
model 2 (0 = 0.080) (Table 2).
TXNIP DNA methylation and gene expression in skeletal muscle
There were no significant differences in skeletal muscle TXNIPDNA methylation or expres-
sion between groups (Figs 2B and 3B, Table 2).
TXNIP DNA methylation in blood
There were no differences in blood TXNIPDNA methylation between the groups (Fig 2C,
Table 2).
Table 1. (Continued)
O-GDM O-T1DM O-BP O-GDM vs. O-BP p-
value
O-T1DM vs. O-BP p-
value
Total cholesterol (mmol/l) 4.68 (4.51–
4.84)
4.70 (4.53–
4.89)
4.78 (4.56–
5.02)
0.447 0.592
Hs-CRP(mg/l) 1.02 (0.81–
1.28)
1.17 (0.90–
1.52)
0.87 (0.66–
1.14)
0.369 0.124
Data is mean (SD), median (25th–75th percentiles) or percentage (number), unless otherwise indicated.
All comparisons are to the O-BP control group. Analysis of differences (means or proportions) between groups performed by independent samples t-test or
X2- test, respectively. P-values < 0.05 are bold. Total body fat % = (total fat mass/total body mass)x100.
*Data on smoking status was missing for 33 subjects
a
. Based on 2-hour 75g OGTT and evaluated according to WHO-criteria of 2006 (ref. [30])
b
. Data is presented as geometric mean and 95% confidence intervals
Abbreviations: BMI: body mass index; HDL: high density lipoprotein; HOMA-IR: homeostatic model assessment insulin resistance; Hs-CRP: high
sensitivity C-reactive protein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; LDL: low density lipoprotein; NA: not applicable; OGTT: oral
glucose tolerance; T1DM: type 1 diabetes; T2DM: type 2 diabetes
https://doi.org/10.1371/journal.pone.0187038.t001
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Fig 2. TXNIP DNA methylation in A. subcutaneous adipose tissue, B. skeletal muscle and C. blood
from offspring of women with gestational diabetes (O-GDM), offspring of women with type 1 diabetes
(O-T1DM) in pregnancy, and offspring of women from the background population (O-BP). Data is
presented as mean +/- SD. Differences between mean of exposure and control groups calculated using
independent samples t-test. All comparisons are to the O-BP control group. DNA methylation was measured
at the CpG site cg19693031. * P<0.05.
https://doi.org/10.1371/journal.pone.0187038.g002
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Association between maternal blood glucose levels and offspring TXNIP
DNA methylation and gene expression
Maternal blood glucose values (fasting or 2-hour for women with GDM and mean blood glu-
cose values in 1st or 3rd trimester for women with T1DM) were not associated with TXNIP
DNA methylation in SAT, skeletal muscle or blood in neither univariate nor multivariate lin-
ear regression analyses. Maternal 1st trimester blood glucose values were significantly nega-
tively associated with SAT TXNIP gene expression in model 1 (p = 0.011) and remained
significant in model 2 (p = 0.024).
Correlations between TXNIP DNA methylation and offspring markers of
glucose and insulin sensitivity in the cohort as a whole
There was a negative association between SAT TXNIPDNA methylation and offspring
120-min plasma glucose values and total body fat %. Skeletal muscle TXNIPDNA methylation
was negatively associated with offspring fasting plasma glucose only. Blood TXNIPDNA meth-
ylation was significantly negatively associated with offspring fasting plasma glucose and insulin
and HOMA-IR (Table 3). Although associations were attenuated, the patterns in associations
in the offspring groups individually were similar to those in the cohort as a whole (S1 Table).
Table 2. TXNIP DNA methylation and gene expression in subcutaneous adipose tissue, skeletal muscle and blood from offspring of women with
gestational diabetes (O-GDM) or type 1 diabetes (O-T1DM) compared to offspring of women from the background population (O-BP) in univariate
and multivariate analyses.
O-GDM O-T1D O-BP O-GDM vs. O-BP p-
value
O-T1DM vs. O-BP p-
value
TXNIP methylation subcutaneous adipose tissue (%);
• O-GDM N = 53; O-T1DM N = 49; O-BP N = 35
39.73
(4.48)
37.76
(4.29)
37.66
(4.18)
0.032
• Model 1 0.063
• Model 2 0.166
0.909
• Model 1 0.336
• Model 2 0.419
TXNIP methylation skeletal muscle (%)
• O-GDM N = 62; O-T1DM N = 62; O-BP N = 41
65.14
(4.42)
63.91
(4.39)
63.56
(4.59)
0.084
• Model 1 0.188
• Model 2 0.369
0.697
• Model 1 0.369
• Model 2 0.440
TXNIP methylation blood (%)
• O-GDM N = 82; O-T1DM N = 65; O-BP N = 57
64.75
(6.66)
64.27
(6.84)
66.25
(8.07)
0.232
• Model 1 0.549
• Model 2 0.627
0.144
• Model 1 0.430
• Model 2 0.511
TXNIP expression subcutaneous adipose tissue
(arbitrary units)a
• O-GDM N = 58; O-T1DM N = 59; O-BP N = 42
1.29 (0.56) 1.53 (0.76) 1.91 (1.25) 0.001
• Model 1 0.024
• Model 2 0.080
0.058
• Model 1 0.271
• Model 2 0.668
TXNIP expression skeletal muscle (arbitrary units)a
• O-GDM N = 76; O-T1DM N = 63; O-BP N = 42
1.09 (0.47) 1.09 (0.48) 1.06 (0.45) 0.800
• Model 1 0.574
• Model 2 0.722
0.786
• Model 1 0.790
• Model 2 0.751
Data is mean (SD). All comparisons are to the O-BP control group. Analysis of differences (means or proportions) between groups was performed by
independent samples t-test.
p-values < 0.05 are bold
TXNIP expression is calculated relative to the HPRT reference gene.
a Data was log transformed prior to t-test.
Model 1: adjusted for maternal pre-pregnancy BMI, age at delivery, smoking status, family history of diabetes, and offspring gender and age at follow-up
Model 2: model 1 with additional adjustment for offspring HOMA-IR, Hba1c, and total body fat percent.
https://doi.org/10.1371/journal.pone.0187038.t002
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Fig 3. TXNIP gene expression in A. subcutaneous adipose tissue and B. skeletal muscle from
offspring of women with gestational diabetes (O-GDM), offspring of women with type 1 diabetes
(O-T1DM) in pregnancy, and offspring of women from the background population (O-BP). Data is
presented as geometric mean with 95% confidence intervals. Differences between mean of exposure and
control groups calculated using independent samples t-test. All comparisons are to the O-BP control group.
Gene expression levels are shown relative to the HPRT reference gene. **P<0.01.
https://doi.org/10.1371/journal.pone.0187038.g003
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Correlations between TXNIP gene expression and offspring markers of
glucose and insulin sensitivity in the cohort as a whole
There was a significant negative correlation between SAT TXNIP gene expression and off-
spring fasting plasma glucose, Hba1c, HOMA-IR, fasting and 2-hour OGTT plasma insulin
levels as well as offspring total body fat percent. By contrast, there was a significant positive
correlation between skeletal muscle TXNIP gene expression and offspring 2-hour OGTT
plasma glucose levels, HOMA-IR, fasting and 2-hour OGTT insulin levels, and total body fat
percent (Table 3). Again, similar patterns were seen when examining offspring groups individ-
ually, although attenuated (S1 Table).
Differences in TXNIP DNA methylation and gene expression in offspring
with prediabetes
We found significantly decreased SAT TXNIPDNA methylation (p = 0.031) and in skeletal
muscle increased TXNIP gene expression (p = 0.038) and borderline decreased TXNIPDNA
methylation (p = 0.070) in offspring with abnormal glucose tolerance (impaired fasting glucose
IFT, impaired glucose tolerance IGT, and T2DM) compared to those with normal glucose tol-
erance (Table 4). There were no differences in blood TXNIPDNA methylation or SAT gene
expression between offspring with abnormal glucose tolerance compared to offspring with
normal glucose tolerance.
Table 3. Correlations between TXNIP DNA methylation and gene expression and offspring markers of metabolic disease.
METHYLATION GENE EXPRESSION
TXNIP DNA
methylation SAT
TXNIP DNA methylation
skeletal muscle
TXNIP DNA
methylation blood
TXNIP gene
expression SAT
TXNIP gene expression
skeletal muscle
TXNIP DNA methylation
SAT
0.282 (0.002) 0.048 (0.576) 0.026 (0.791)a -0.225 (0.011) a
TXNIP DNA methylation
skeletal muscle
muscle
0.282 (0.002) 0.220 (0.005) 0.004 (0.964) a -0.128 (0.104) a
TXNIP DNA methylation
blood
0.048 (0.576) 0.220 (0.005) 0.090 (0.265) a 0.061 (0.420) a
TXNIP gene expression
SAT
0.026 (0.791)a 0.004 (0.964) a 0.090 (0.265) a -0.092 (0.265) a
TXNIP gene expression
skeletal muscle
0.225 (0.011) a -0.128 (0.104) a 0.061 (0.420) a -0.092 (0.265) a
Fasting plasma glucose
(mmol/l)
-0.104 (0.228) -0.177 (0.023) -0.143 (0.041) -0.176 (0.027) a 0.049 (0.516) a
120-min plasma glucose
(mmol/l)
-0.222 (0.011) -0.108 (0.177) 0.011 (0.882) -0.151 (0.065) a 0.272 (<0.001) a
HbA1C DCCT (%) 0.093 (0.279) 0.005 (0.946) -0.103 (0.144) -0.211 (0.008) a 0.044 (0.554) a
HOMA-IR -0.040 (0.661) -0.111 (0.181) -0.156 (0.035) -0.408 (<0.001) a 0.256 (0.001) a
Fasting insulin (pmol/l) -0.021 (0.814) -0.080 (0.334) -0.151 (0.041) -0.400 (<0.001) a 0.254 (0.001) a
120-min insulin (pmol/l) -0.105 (0.244) -0.081 (0.322) -0.064 (0.385) -0.300 (<0.001) a 0.409 (<0.001) a
Total body fat (%) -0.175 (0.041) -0.063 (0.426) 0.010 (0.882) -0.289 (<0.001) 0.349 (<0.001)
Correlations are presented as Pearsons rank coefficient R (p-value) unless otherwise indicated. P-values <0.05 are bold.
aSpearman’s rank coefficient.
SAT: subcutaneous adipose tissue
HOMA-IR: homeostatic model assessment insulin resistance
https://doi.org/10.1371/journal.pone.0187038.t003
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Discussion
In this study, we were unable to confirm our a priori hypothesis of decreased TXNIPDNA
methylation and increased gene expression in adult offspring of women with diabetes in preg-
nancy compared to controls. In contrast, we found an unexpected increased SAT TXNIPDNA
methylation and a decreased TXNIP gene expression in the O-GDM subgroup. There were no
significant differences in skeletal muscle or blood TXNIPDNA methylation or skeletal muscle
gene expression between groups.
TXNIP DNA methylation in blood
Although the differences were not statistically significant, the exposure groups in our cohort
tended to have decreased blood TXNIPDNA methylation and blood TXNIPDNA methylation
was significantly negatively associated with offspring fasting plasma glucose and insulin and
HOMA-IR (Table 3). This is in line with previous findings of an inverse association between
blood TXNIPDNA methylation levels and fasting plasma glucose and Hba1c levels, and
between blood TXNIPDNA methylation and risk of T2DM [14–16, 18, 19], as well as
decreased blood TXNIPDNA methylation in subjects with T2DM compared to controls [17].
While most of these studies included between 1,100 and 20,000 participants, of whom between
200 and 1,900 had T2DM, there were only a total of 23/206 (11%) subjects with abnormal glu-
cose tolerance or T2DM in our study (O-GDM, n = 11; O-T1DM, n = 9; O-BP, n = 3), with
the majority of participants having normal glucose tolerance. Thus, the lack of difference in
TXNIP blood DNA methylation between exposure and control groups could be due a type 2
error, since we observed an expected trend of decreased methylation in blood in both exposure
groups.
TXNIP DNA methylation in tissues
To date, only one other study has examined TXNIPDNA methylation in tissues besides blood,
finding decreased TXNIPDNA methylation in skeletal muscle and pancreatic islets, but no dif-
ference in adipose tissue TXNIPDNA methylation, in subjects with T2DM compared to con-
trols [17]. By contrast, we found increased SAT TXNIPDNA methylation and no difference in
Table 4. TXNIP DNA methylation and gene expression in subjects with normal glucose tolerance compared to subjects with prediabetes.
Abnormal OGTT (IFG, IGT, or
T2DM)
Normal
OGTT
Difference between subjects with normal and abnormal
OGTT (p-value)
TXNIP DNA methylation SAT (N = 14/123) 36.73 (2.81) 38.70 (4.53) 0.031
TXNIP DNA methylation skeletal muscle
(N = 18/147)
62.48 (3.91) 64.50 (4.51) 0.070
TXNIP DNA methylation blood (N = 23/
181)
65.88 (5.67) 64.91 (7.32) 0.540
TXNIP gene expression SATa (N = 21/138) 1.52 (0.78) 1.55 (0.91) 0.962
TXNIP gene expression skeletal musclea
(N = 21/160)
1.26 (0.46) 1.06 (0.47) 0.038
Data is mean (SD). Analysis of differences between groups was performed by independent samples t-test.
p-values < 0.05 are bold
N refers to number of subjects with abnormal OGTT vs. subjects with normal OGTT for each analysis
a Data was log transformed prior to t-test.
Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pone.0187038.t004
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skeletal muscle TXNIPDNA methylation in subjects predisposed to T2DM via fetal program-
ming. These results, contrasting our a priori hypothesis, therefore do not suggest that altered
TXNIPDNA methylation levels in SAT and skeletal muscle are responsible for the metabolic
impairment observed in offspring exposed to maternal diabetes.
The increased SAT TXNIPDNA methylation in O-GDM in our cohort is furthermore in
contrast to the findings of TXNIP blood and skeletal muscle hypomethylation with increasing
Hba1c levels, increased risk of T2DM and overt T2DM [14–18], but the different tissues stud-
ied could explain the different results. Interestingly, in a post hoc subject stratification, we
found decreased TXNIP SAT DNA methylation in subjects with abnormal glucose tolerance
compared to those with normal glucose tolerance, similar to previous findings in blood and
skeletal muscle. Although speculative due to the post hoc explorative subgroup analysis, this
does provide some evidence that ambient plasma glucose levels, and not exposure to maternal
diabetes, could be responsible for changes in TXNIPDNA methylation.
TXNIP gene expression
The decreased SAT TXNIP expression in the exposure groups differs from a previous study
which demonstrated increased TXNIP expression in cultured human adipocytes in response to
glucose [22]. However, comparison between this study and our results is difficult because the
in vitro effect of glucose on cells in culture cannot be directly extrapolated to gene expression
levels in human biopsies. One study found that TXNIP knockout mice were protected against
insulin resistance when challenged with a high-fat diet, remaining more insulin-sensitive than
controls despite gaining more adipose tissue mass due to increased rates of insulin-stimulated
glucose uptake in both skeletal muscle and adipose tissue [31]. Another study showed that
TXNIP expression is inversely correlated with glucose-uptake in insulin-sensitive cells and tis-
sues including adipocytes and skeletal muscle [22]. The lower SAT TXNIP gene expression lev-
els could therefore be a compensatory mechanism that contributes toward slowing the natural
disease process by increasing peripheral glucose uptake and maintaining insulin sensitivity in
subjects at increased risk of future T2DM. This is supported by findings of no difference in
adipose tissue TXNIP expression in subjects with T2DM compared to controls [17], indicating
a lack of these compensatory mechanisms in subjects with overt disease. The similar findings
of decreased TXNIP SAT expression in both O-GDM and O-T1DM (although only near-sig-
nificant for O-T1DM) lend added credibility to our results, but studies of TXNIP expression in
SAT are scarce, and we cannot exclude that our findings could be part of an as yet unknown
pathogenic mechanism.
Studies have demonstrated decreased skeletal muscle and blood TXNIPDNA methylation
and increased skeletal muscle TXNIP expression in subjects both at increased risk of as well as
overt T2DM, and hyperglycemia increases TXNIP expression in various cells and tissues [17,
18, 22]. Therefore, we examined differences in TXNIPDNA methylation and expression in the
23 offspring with abnormal glucose tolerance (impaired fasting glucose IFG, impaired glucose
tolerance IGT, or T2DM) compared to those with normal glucose tolerance. The increased
skeletal muscle TXNIP gene expression (and borderline reduced TXNIPDNA methylation) in
the subgroup of 23 offspring with abnormal glucose tolerance is in support of previous find-
ings of increased skeletal muscle TXNIP expression in subjects with prediabetes and diabetes
[22]. The lack of difference in skeletal muscle TXNIP expression in exposed offspring in our
cohort could therefore be due to the fact that the majority of our subjects showed normal glu-
cose tolerance and similar fasting blood glucose levels. These results thereby suggest that
changes in SAT and skeletal muscle TXNIPDNA methylation and gene expression are more
likely to be mediated by plasma glucose levels than to be a consequence of fetal programming.
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Tissue-specific differences in correlation between TXNIP gene
expression and offspring parameters of glucose and insulin sensitivity
Interestingly, correlations between TXNIP expression and parameters of glucose and insulin
sensitivity (fasting and 2-hour OGTT plasma glucose and insulin levels, HbA1c, HOMA-IR
and total body fat percent) were tissue specific and opposite for SAT vs. skeletal muscle, with
overall negative correlations in SAT but positive correlations in skeletal muscle. Thus, our
results indicate tissue-specific differences in TXNIP expression that make it difficult to extrap-
olate information between different tissue types. These tissue-specific differences also provide
a possible explanation for findings in other studies of decreased TXNIPDNA methylation and
increased expression in skeletal muscle to be associated with T2DM, while we found increased
SAT TXNIPDNA methylation and decreased gene expression in O-GDM in our cohort.
Exposure to diabetes in pregnancy
O-T1DM are likely exposed to higher blood glucose levels in pregnancy, as evidenced by the
fact that a larger proportion of O-T1DM were born large for gestational age compared to
O-GDM [24], and the fact that GDM mothers in our cohort were diet-treated only. However,
the greater difference in both methylation and gene expression in SAT for O-GDM suggest a
role for factors besides maternal glucose levels alone playing a role on offspring metabolic phe-
notype. These factors include genes (O-GDM are expected to have greater genetic predisposi-
tion to T2DM), lifestyle, social and environmental factors, as well as potential intrauterine
metabolites besides glucose (eg. amino acid or fatty acids).
The increased SAT TXNIPDNA methylation in O-GDM disappeared after adjustment for
the offspring´s ambient insulin resistance (HOMA-IR), HbA1c levels and total body fat%
(model 2, see Results section). However, SAT and muscle TXNIP functions are suspected to
regulate tissue and whole body glucose uptake. Thus, cause-effect relationships between tissue
TXNIPmeasurements on one side, and HbA1c, HOMA-IR and body fat % on the other, are
unclear, why no clear conclusions can be drawn from changes in tissue TXNIPmeasurements
after correction for the offspring´s ambient HbA1c, HOMA-IR and total body fat % levels.
Strengths and limitations
The strength of our study lies in the availability of simultaneous information regarding methyl-
ation and gene expression in adipose tissue, skeletal muscle and blood from a relatively large,
unique cohort of adult offspring exposed to maternal hyperglycemia. Especially in SAT and
skeletal muscle, data regarding TXNIPDNA methylation is scarce and this study provides
some of the first available knowledge about TXNIPDNA methylation levels in these tissues.
Additionally, our sample size is relatively large, as many epigenetic studies investigating gene
expression and DNA methylation in metabolically active tissues such as skeletal muscle and
SAT include about 20 subjects in each group [32, 33].
Our study is performed on adult offspring, and the study design does not allow us to estab-
lish causality; Furthermore, we cannot say with certainty whether the absolute differences in
average DNA methylation and gene expression observed between the exposure groups and the
control group are a consequence of intrauterine exposure to maternal diabetes or a conse-
quence of other factors pertaining to lifestyle and genetics that we cannot account for. How-
ever, the fact that the study includes adult offspring can also be viewed as a potential strength,
as there are very few other studies examining epigenetic changes in adult offspring exposed to
maternal diabetes, and the findings may indicate that epigenetic changes occurring as a result
of detrimental fetal exposures have the potential to last a lifetime.
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The participation rate from the first to second follow-up, between which there was
approximately a 10-year gap, was 45% (206/456 = 45%), and 25% (206/812 = 25%) from the
original cohort. Although a potential weakness, this is also a well-known limitation to studies
where cohorts are followed over long periods of time. Moreover, there was a certain selection
bias between the two rounds of follow-up as many subjects with impaired glucose metabo-
lism in the first follow-up declined participation in the second follow-up, as described previ-
ously [24]. Our cohort is thus essentially composed of the healthiest subjects from the
original cohort—however, this would tend to push towards an underestimation of the
results. Finally, many comparisons have been performed without correction for multiple
testing and with all significance levels provided as nominal significance, potentially increas-
ing the risk of type 1 errors.
Conclusion
In conclusion, our results suggest that decreased TXNIPDNA methylation and increased gene
expression are unlikely to represent major pathogenic mechanisms in fetal programming of
metabolic disease caused by exposure to maternal diabetes. Further studies are needed to con-
firm our unexpected findings of increased TXNIPDNA methylation as well as decreased
TXNIP gene expression in the subgroup of O-GDM.
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